Publication Date

2013

Abstract

The US Food and Drug Administration ( FDA ) required a reevaluation of cardiovascular ( CV ) outcomes in the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as well as to use new FDA end point definitions in development.

School/Institute

Mary MacKillop Institute for Health Research

Document Type

Open Access Journal Article

Access Rights

Open Access

Notes

© 2013, The Authors. Published by Mosby, Inc. Open access under CC BY-NC-ND license

Included in

Cardiology Commons

Share

COinS